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Varicella-zoster virus (VZV) establishes lifelong neuronal latency in most humans world-
wide, reactivating in one-third to cause herpes zoster and occasionally chronic pain. How
VZV establishes, maintains and reactivates from latency is largely unknown. VZV tran-
scription during latency is restricted to the latency-associated transcript (VLT) and RNA 63
(encoding ORF63) in naturally VZV-infected human trigeminal ganglia (TG). While sig-
nificantly more abundant, VLT levels positively correlated with RNA 63 suggesting co-
regulated transcription during latency. Here, we identify VLT-ORF63 fusion transcripts and
confirm VLT-ORF63, but not RNA 63, expression in human TG neurons. During in vitro
latency, VLT is transcribed, whereas VLT-ORF63 expression is induced by reactivation sti-
muli. One isoform of VLT-ORF63, encoding a fusion protein combining VLT and ORF63
proteins, induces broad viral gene transcription. Collectively, our findings show that VZV
expresses a unique set of VLT-ORF63 transcripts, potentially involved in the transition from
latency to lytic VZV infection.
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The ubiquitous human neurotropic alphaherpesvirus (αHV)varicella-zoster virus (VZV) establishes lifelong latency insensory neurons of dorsal root and cranial nerve ganglia, as
well as autonomic and enteric ganglia1,2. VZV reactivates in
about one-third of latently infected individuals to cause herpes
zoster (HZ), a debilitating disease often complicated by post-
herpetic neuralgia (PHN)3,4. The incidence and severity of HZ are
closely related to declining VZV-specific T-cell immunity by
natural senescence5, and immunosuppressive diseases6. However,
the mechanisms governing how VZV reestablishes a lytic infec-
tion from latency in neurons, especially the identity of the viral
gene(s) that initiate reactivation in response to cellular signaling,
remain unknown.
During latency in human trigeminal ganglia (TG), VZV gene
expression is restricted to transcripts arising from VLT (VZV
latency-associated transcript) and ORF63 loci7. VLT is a poly-
adenylated RNA comprising five exons that lie partially antisense
to VZV ORF61, the infected cell polypeptide 0 (ICP0) homologue
conserved among αHV. Based on genomic location and expres-
sion pattern, VLT is considered a homologue of the latency-
associated transcripts (LATs) encoded by all other well-studied
neurotropic αHVs8. While VLT is the most prevalent and
abundant VZV transcript expressed in human TGs, lower levels
of ORF63 RNA have also been reported in up to 70% of examined
latently VZV-infected ganglia7,9. This apparent expression of two
distinct viral transcripts during latency is unique among well-
studied αHV. Expression levels of VLT and ORF63 transcripts
correlate significantly7, suggesting co-regulated expression of
both transcripts during in vivo latency, and that these transcripts
and/or their encoded proteins may play an important role in the
VZV latency and reactivation cycle. VLT is expressed during both
latent and lytic VZV infection7. Intriguingly, VLT isoforms
expressed during lytic VZV infection (lytVLT) differ extensively
from the latent VLT isoform in that they contain additional
upstream exons and show evidence of alternative splicing by exon
skipping or intron retention7. Furthermore, a long-read cDNA
sequencing approach recently reported the presence of lytVLT
splicing into the ORF63 transcripts during lytic VZV infection10,
raising the possibility that individual transcripts may span the
VLT and ORF63 loci.
Here, we set out to characterize the expression patterns and
functional importance of VLT and ORF63 encoding RNAs during
lytic and latent infections. We apply nanopore direct RNA
sequencing (dRNA-Seq)11 to examine lytically VZV-infected
epithelial cells and discover a novel set of VLT-ORF63 fusion
transcripts, which are also present in latently VZV-infected
human TG and our recently improved in vitro VZV human
neuronal latency model based on human induced pluripotent
stem cell (iPSC)-derived sensory neurons (HSN)7,12.
Results
Identification of multiple VLT-ORF63 fusion transcripts in
lytically VZV-infected cells. Sequencing of full-length RNAs,
including direct RNA sequencing (dRNA-Seq), is particularly
useful for disentangling complex loci at which multiple transcript
isoforms overlap13,14. Recently, we used dRNA-Seq to reannotate
the lytic VZV transcriptome and redefined the kinetic classes of
all canonical and newly identified transcript isoforms15. Here, we
performed more detailed dRNA-Seq analysis of the VLT and
ORF63 loci in lytically VZV-infected human retina epithelial
(ARPE-19) cells, identifying multiple lytic VLT (lytVLT) isoforms,
all of which contain one or more upstream exons to the core VLT
region (exons 1–5) that defines the latent isoform, referred to as
VLT7. By far the most common lytVLT variants utilized a single
upstream exon designated as exon A (Fig. 1a). We additionally
identified several relatively abundant transcripts that spanned the
VLT and ORF63 loci, lytVLT-ORF63 fusion transcripts hereafter
referred to as lytVLT63. Two major lytVLT63 isoforms (i.e.
lytVLT63-1 and lytVLT63-2) represent alternatively spliced var-
iants of a lytic VLT isoform comprising the VLT core region, the
additional upstream exon A, and the RNA 63-1 encoding cano-
nical ORF6315. lytVLT63-1 and lytVLT63-2 differ from each other
by skipping or retaining VLT exon 5, respectively. Both isoforms
use a splice acceptor site located 71 nucleotides (nt) upstream of
the ORF63 coding sequence (CDS), located within the 5′-
untranslated region (UTR) of canonical ORF6315–17. A third
major isoform, lytVLT63-3 utilizes a unique transcription start
site (TSS), not used by any of the other lytVLT and lytVLT63
isoforms, proximal to exon 5 and is predicted to encode pORF63
(Fig. 1a).
To investigate the effect of cell type on lytic transcription
across the VLT and ORF63 loci, we assayed our in vitro HSN
model that supports both lytic and latent VZV infection12. The
low yields of viral RNA obtained from infected HSN cultures
necessitated the use of nanopore cDNA sequencing (cDNA-Seq)
rather than dRNA-Seq. Notably, the same lytVLT and lytVLT63
isoforms were detected in lytically VZV-infected HSN and ARPE-
19 cells by both nanopore sequencing (Fig. 1a) and RT-qPCR
(Fig. 1b) using primer sets spanning lytVLT63 isoform-defining
exons (Supplementary Fig. 1 and Supplementary Table 1).
Collectively, these data indicate that identical repertoires of
lytVLT and lytVLT63 isoforms are expressed during lytic VZV
infection in human sensory neurons and epithelial cells.
VLT-ORF63 explains co-regulated VLT and RNA 63 tran-
scription in latently VZV-infected human TG. RT-qPCR was
performed on four human TG specimens to determine whether
viral RNA detected in latently VZV-infected TG should be
ascribed to the pORF63 encoding RNA 63-1 transcript and/or the
VLT-ORF63 fusion transcripts VLT63-1 and VLT63-2 (Supple-
mentary Table 2). Consistent with our earlier study7, VLT but not
lytVLT (i.e. no detectable presence of exon A) was detected in all
TG analyzed, while the ORF63 CDS region of RNA 63-1 was
detected in 3 of 4 specimens (Fig. 2a). Similarly, splice junction
usage between VLT exon 4 and RNA 63-1, and exon 5 and RNA
63-1 was detected in all three TGs positive for the ORF63 CDS
region (Fig. 2a). No transcripts were detected using a primer set
targeting the 5′ UTR region of canonical RNA 63-1 that is absent
in all VLT-ORF63 transcripts (Supplementary Fig. 1). These
results imply that VLT and VLT63 isoforms, but not lytVLT,
lytVLT63 isofoms, nor RNA 63-1 are expressed in latently VZV-
infected human TG.
We next performed multiplex fluorescent in situ hybridization
(mFISH) using probes directed to the VLT and ORF63 CDS to
simultaneously profile VLT, VLT63-1, VLT63-2, and RNA 63-1
expression in the same TG section. During lytic infection in HZ
skin biopsies (Fig. 2b, lower panels) and ARPE-19 cells
(Supplementary Fig. 2a), VLT and ORF63 CDS ISH signal
showed partial co-localization within the nucleus and largely
divergent localization within the cytoplasm of VZV-infected cells.
Analysis of seven additional human TGs (Supplementary Table 3)
confirmed nuclear VLT RNA (Fig. 2b, middle panels) or co-
localization of nuclear VLT and ORF63 CDS ISH signals (Fig. 2b,
upper panels) in VZV-infected neurons. Notably, the two ISH
signals co-localized in the vast majority of neurons (i.e. 4-11
neurons/section, present in all 7 TGs analyzed). Only a small
number of neurons, 4 neurons in total and in just 2 of 7 TGs
analyzed, yielded staining that showed distinct puncta (Supple-
mentary Fig. 2b). To exclude VZV reactivation in neurons
expressing VLT63 we performed mFISH using probes directed to
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VLT, the ORF63 CDS, and a region of the ORF9 loci which
encodes multiple transcripts including RNA 9-1, the most
abundantly lytic transcript. Here, strong ISH signal for VLT
and ORF63 CDS was observed in VZV-infected epithelial cells
present in both HZ skin biopsies (Supplementary Fig. 3a) and
latently infected neurons, whereas ISH signal for RNA 9 was only
observed in the skin biopsies (i.e. no RNA 9 transcripts present in
latently infected neurons). Thus, co-localization of VLT and
ORF63 CDS ISH signal during latency provides further support
for the presence of the VLT63-1 and VLT63-2 fusion transcripts
in latently VZV-infected human TG.
To further characterize and differentiate VLT, VLT63-1,
VLT63-2, and RNA 63-1 transcripts in human TGs, 5′-RACE
analysis was performed on pooled poly(A)-selected RNA
collected from 3 TGs with detectable VLT-ORF63 fusion
transcripts (i.e. TG 2–4 in Fig. 2a). The VLT-specific reverse
primers (VLTexon4R104361 and VLTexon5R104799 in Fig. 2c
and Supplementary Table 4) identified two alternative TSS
located 4 nt upstream and 21 nt downstream of VLT exon 1
(Fig. 2c, orange arrows in top row), and detected only VLT with
no alternatively spliced isoforms (Fig. 2c, orange boxes). The




































































































Fig. 1 Transcription profile across the VLT and ORF63 loci during lytic VZV infection of human epithelial cells and sensory neurons. a Coverage plots
denoting dRNA-Seq (ARPE-19 epithelial cells, dark blue) and cDNA-Seq (human iPSC-derived sensory neurons [HSN], teal) data aligned to the top strand
of the VZV genome. dRNA-Seq data is representative of two independently sequenced biological replicates with RNA extracted from lytically VZV-infected
ARPE-19 cells at 4 days post infection (4 dpi). cDNA-Seq data was generated from a pool of biological replicates collected from lytically VZV-infected HSN
at 14 dpi. Schematics of the major transcripts from VLT and ORF63 loci are shown in following colors: lytic VLT isoform (lytVLT, red), canonical RNA 63-1
(63, green), lytic VLT-ORF63 isoforms (lytVLT63-1/2/3, purple) and latent VLT isoform (VLT, orange). Additional canonical VZV transcription units
present are shown in grey, with ORF numbers indicated. Wide boxes indicate canonical CDS domains and while thin boxes indicate UTRs, respectively. Y-
axis values indicate the maximum read depth of that track. b Analysis of VLT, RNA 63 and VLT-ORF63 isoform expression by RT-qPCR analysis using the
same two independent experiments in ARPE-19 cells (dark blue) and HSN (teal) for long-read sequencing. The primer locations used for RT-qPCR analysis
detecting transcripts from VLT to ORF63 loci are depicted in Supplementary Fig. 1. Source data are provided as a Source Data file. ORF; open reading frame,
CDS; coding sequence, UTR; untranslated region.
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ORF63R805 in Fig. 2c and Supplementary Table 4) identified
only two VLT-ORF63 isoforms, VLT63-1 and VLT63-2 with
alternative splicing donor sites located in VLT exons 4 and 5,
respectively (Fig. 2c, teal boxes). Note that VLT63-1 and VLT63-2
are identical to lytVLT63-1 and lytVLT63-2 respectively expressed
during lytic VZV infection, except for the unique 5′ ends that
discriminate latent isoform from lytVLT variants (Fig. 1a).
Importantly, the TSS for all RNAs containing RNA 63-1 sequence
in human TG were located close to VLT exon 1 and were part of
the VLT-ORF63 fusion transcripts (Fig. 2c, teal arrows), while no
canonical RNA 63-1 transcripts were detected. Collectively, these
results implicate that most – if not all – RNA 63-1 previously
detected in latently VZV-infected human TG is attributed to
VLT63-1 and VLT63-2 transcript expression.
Protein coding potential differs between VLT-ORF63 tran-
script isoforms. In silico translation of the major lytic VLT-ORF63
isoforms, lytVLT63-1 and lytVLT63-2, predicted novel proteins
(Fig. 3a and Supplementary Fig. 4), whereas lytVLT63-3 (Fig. 1a)
appears to encode solely canonical ORF63 protein (pORF63).
Importantly, exon A utilized in lytic isoforms does not affect the
protein coding potential, suggesting that the respective latent and
lytic isoforms encode the same protein i.e. VLT and lytVLT are both
predicted to encode identical version of pVLT (Fig. 3a). VLT63-1
(lytVLT63-1) encodes a putative in-frame fusion protein called
pVLT-ORF63. The pVLT-ORF63 is predicted to be 421 amino
acids (aa) in length, comprising partial pVLT (aa 1-119) and the
canonical pORF63 (278 aa) linked together by 24 aa polypeptide
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Fig. 2 Transcription profile across the VLT and ORF63 loci in latently VZV-infected human trigeminal ganglia. a Detection of VLT, canonical RNA 63-1
and VLT63 isoforms by RT-qPCR analysis in latently VZV-infected human trigeminal ganglia (TG) (n= 4; post-mortem interval 4–4.5 h). Data on individual
TG samples are shown as unique symbols. Source data are provided as a Source Data file. b Detection of VZV RNA 63 and VLT RNA by multiplex
fluorescent in situ hybridization (ISH) on human TG (upper two panels) and human herpes zoster skin biopsy (bottom panel). Representative images are
shown for n= 7 human TG and n= 2 zoster skin biopsies. Asterisks indicate autofluorescent lipofuscin granules in neurons. Scale bar: 10 µm. Arrowheads
indicate RNA 63 (red) and/or VLT (green) ISH signal. Right panels: enlargements of area indicated by white box. c Putative transcription start sites (TSS)
of VLT (row 1), VLT63 (row 2) in human TGs and VLT in latently VZV-infected human iPSC-derived sensory neurons (HSN) (row 3), as determined by 5′-
RACE analysis. Schematic top shows major latent VLT and VLT-ORF63 transcript isoforms and location of primers used for 5′-RACE analysis. Bottom: VLT
sequence of VLT exon 1, as previously determined by RNA-seq on human TGs7. Flanking regions are shown with arrows indicating putative TSS by 5′-RACE
analysis.
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64 aa pORF63 : 278 aa
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Fig. 3 Protein coding potential of VLT-ORF63 fusion transcripts. a Schematic presentation of VLT and VLT-ORF63 isoform transcripts with predicted
encoded proteins. Red boxes indicate exons of lytic isoforms of VLT and VLT-ORF63 transcripts, orange boxes indicate exons of latent isoforms of VLT and
VLT-ORF63 transcripts, and a black box indicates a part of RNA 63-1 5′-UTR in canonical RNA 63-1 transcript. The end of VLT-ORF63 transcripts indicates
stop codon for ORF63 CDS. Black horizontal lines indicate location of encoded open reading frames (ORFs). The blue square indicates the first start codon
(ATG), the black triangle indicates first stop codon within the same frame as the start codon, the green diamond indicates start codon of canonical ORF63,
and grey circles indicate downstream ATG codons within the same frame as the start codon. Pointed rectangles show translated protein from
corresponding ORFs with a black box indicating the 24 amino acid linker peptides translated from a part of RNA 63-1 5′-UTR in the canonical RNA 63-1
transcript. UTR; untranslated region, CDS; coding sequence. Confocal microscopic images of ARPE-19 cells b transfected with CS-CA-VZV plasmids (48 h
post transfection), c lytically infected with VZV (4 dpi), and d herpes zoster skin lesions. b, c Cells were stained with anti-pORF63 mAb (green) and anti-
pORF63 pAb (red) for CS-CA-ORF63, and anti-pVLT-ORF63 pAb (green), anti-pVLT pAb (red) and anti-pORF63 mAb (blue) for CS-CA-VLT-ORF63-1 and
CS-CA-VLT-ORF63-2 and lytic VZV infection. Nuclei were stained with DAPI (cyan) and images are representative of results from two independent
experiments. Magnification; x600 and x3 digital zoom with 5 µm scale bars (except 3rd row in b, and 3rd and 4th rows in c) and x600 and x2 digital zoom
with 10 µm scale bars (3rd row in b, and 1st and 2nd rows in c). mAb; monoclonal antibody, pAb; polyclonal antibody. d Nuclei were stained with DAPI
(blue) and images are representative for two independent stainings performed on one control and two herpes zoster skin biopsies. Magnification: x200
with 50 µm scale bars (1st and 2nd rows) and x200 and x3 digital zoom with 20 µm scale bars (3rd row).
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5′-UTR of RNA 63-1 (Fig. 3a). The VLT63-2 (lytVLT63-2) isoform
is predicted to encode two separate proteins: complete pVLT (136
aa) and an N-terminally extended 336 aa pORF63 protein variant
(pORF63-N+). pORF63-N+ includes an N-terminal 88 aa poly-
peptide, the first 64 aa of which are translated from VLT exons 4
and 5, but out-of-frame with pVLT, and the same 24 aa linker
polypeptide of pVLT-ORF63 encoded from the partial 5′-UTR of
RNA 63-1 (Fig. 3a).
The protein coding capacity of the VLT-ORF63 isoforms were
examined by immunoblotting of ARPE-19 cells transfected with
plasmids expressing VLT63-1 and VLT63-2, and ORF63 for
comparison, as well as in lytically VZV-infected ARPE-19 cells
using antibodies raised against parts of pVLT and pORF63
(Supplementary Fig. 5). The anti-pVLT antibody (Ab) was raised
against the first 19 aa of pVLT7, being part of both pVLT and
pVLT-ORF63. The anti-pORF63 Ab was raised against whole
pORF637, recognizing pVLT-ORF63, pORF63-N+ and pORF63.
Translation of all predicted proteins from each plasmid was
confirmed in transfected ARPE-19 cells and both pVLT-ORF63
and pORF63-N+ were readily detected in the context of lytic
VZV infection (Supplementary Fig. 5).
Next, we assayed the cellular localization of protein expression
by immunofluorescence. In transfected cells, pORF63 was
detected in the nucleus and particularly in the cytoplasm, whereas
pVLT-ORF63 predominantly localized in the nucleus (Fig. 3b).
Cells transfected with the VLT63-2 vector, predicted to encode
pVLT and the fusion protein pORF63-N+, resulted in nuclear
and cytoplasmic pVLT but undetectable pORF63-N+ expression
(Fig. 3b). In lytically VZV-infected ARPE-19 cells, pVLT-ORF63
localized to the nucleus and cytoplasm, as demonstrated by
immunofluorescent staining with antibodies against pVLT-
ORF63, pVLT and pORF63 (Fig. 3c), possibly indicating that
other viral proteins are required for its retention in cytoplasm or
shuttling between nuclear and cytoplasm. Finally, we confirmed
expression of pVLT-ORF63 and/or pORF63-N+ in the cytoplasm
and, to a lesser degree, in the nucleus of VZV-infected pORF63pos
keratinocytes in HZ skin biopsies (Fig. 3d). Thus, pVLT-ORF63
and/or pORF63-N+ are expressed in VZV-infected cells in vitro
and in vivo.
Treatment with JNK activator promotes VLT-ORF63 tran-
scription in latently VZV-infected sensory neurons. We next
used our in vitro VZV sensory neuronal latency model12 to
examine transcription patterns across the VLT and ORF63 loci by
RT-qPCR during latency and reactivation. Consistent with VZV
latency in human TG, VLT was readily detectable in latently
VZV-infected HSN, while no other tested viral immediate early
(IE), early (E) or late (L) transcripts were detected (Fig. 4a).
Notably, we detected neither RNA 63-1 (CDS and 5′-UTR) nor
any of the VLT-ORF63 isoforms (Fig. 4a), whose absence was
seen only in small fraction of human TGs (Fig. 2a and ref. 7). 5′-
RACE analysis of VLT and ORF63 loci on RNA extracted from
latently VZV-infected HSN confirmed expression of core VLT
isoform and usage of the two VLT TSS detected in human TG as
well as a third TSS located 9 nt upstream of VLT exon 1 (Fig. 2c,
orange arrows in bottom row), while lytVLT and lytVLT63 iso-
forms were not detected.
Similar to previously reported in vitro models for VZV latency
using human embryonic stem cell (hESC)-derived neurons18,19,
induction of complete virus reactivation was relatively inefficient
in our HSN model12. Complete reactivation was observed in 2 of
40 replicates, as demonstrated by the formation of infectious foci
after transferring the HSN onto and co-culturing with ARPE-19
cells (Fig. 4b, upper panel), and associated with expression of all
IE, E and L VZV transcripts tested in the HSN (Fig. 4c, white
circle). Although no infectious virus was recovered from 38
replicates (Fig. 4b, lower panel), low levels of broad viral gene
expression could be detected including VLT63-1 indicative of exit
from latency (Fig. 4c, colored triangles). These data indicate that
VLT expression is a hallmark of VZV latency in human sensory
neurons in vitro, while VLT63-1 and VLT63-2 are induced in
response to reactivation stimuli.
Given the critical role of JNK activation as a trigger of HSV-1
lytic gene expression during reactivation20 as well as the
importance of JNK signal in VZV reactivation21, we speculated
that JNK activation may trigger VZV reactivation by inducing
lytic gene expression. Latently VZV-infected HSN were treated
with the JNK activator anisomycin, a compound that also inhibits
protein synthesis. VZV reactivation, as measured by transferring
HSN onto ARPE-19 cells for infectious focus forming assay, could
not be detected. However, anisomycin treatment consistently
increased VLT expression and induced expression of VLT63-1
and VLT63-2 (Fig. 4d). By contrast, anisomycin treatment
induced only limited expression of transcripts from the RNA 4
(3 of 6 replicates), RNA 61 (5 of 6 replicates) or RNA 9 (1 of 6
replicates) families, while no lytic VZV gene transcription was
detected following mock treatment (Fig. 4e). Thus, anisomycin-
mediated JNK activation and/or inhibition of protein synthesis
selectively and consistently induces transcription of VLT and
both VLT63 isoforms in parallel with or prior to induction of IE
gene transcription.
Ectopic VLT63-1 expression induces broad viral gene expres-
sion in the latently VZV-infected sensory neuron model. The
anisomycin-induced VLT63-1 and VLT63-2 transcription sug-
gested that these transcripts, or their encoded proteins, contribute
to VZV reactivation. To investigate whether VLT63-1 or VLT63-
2 alone can induce VZV reactivation, latently VZV-infected HSN
were transduced with replication-incompetent lentivirus vectors
encoding ORF63, VLT63-1 or VLT63-2 isoforms, or an empty
vector control. Ectopic gene transcription and translation was
confirmed in all transduced cell cultures (Fig. 5a and Supple-
mentary Fig. 6). Both in the empty vector and ORF63-transduced
cells, endogenous VLT was detected by RT-qPCR at comparable
level (Fig. 5a). Sporadic IE and E gene, but no L gene tran-
scription was detected in ORF63- and VLT63-2-transduced cells
(Fig. 5b–d). Notably, transcription of VZV IE, E, and L genes was
consistently induced by ectopic VLT63-1 expression in latently
VZV-infected HSN (Fig. 5b–d). Consistent with the absence or
very low level of RNA 62 transcription, which encodes the major
viral transactivator protein22, no infectious VZV was recovered
from VLT63-1-transduced HSN cells. Given the differences in
protein-coding potential between the VLT63 isoforms and com-
pared to canonical RNA 63-1 (Fig. 3a), the pVLT-ORF63 fusion
protein is potentially involved in the transition from latency to
reactivation in our HSN VZV latency model.
Discussion
VZV latency in human TG is characterized by detection of RNAs
expressed from the VLT and occasionally the ORF63 locus, where
expression levels of both transcripts correlated positively sug-
gesting co-regulated transcription7. Here, we demonstrated that
this pattern is best explained by co-expression of VLT and two
VLT-ORF63 fusion transcripts, VLT63-1 and VLT63-2, and not
by expression of the canonical RNA 63-1 transcripts independent
of VLT. Further characterization of the VLT-ORF63 isoforms,
expressed during both lytic and latent VZV infection, demon-
strated that reactivation stimuli increases VLT and induces
VLT63-1 and VLT63-2 expression in our in vitro VZV HSN
latency model. Moreover, ectopic VLT63-1 expression induced
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broad viral lytic gene transcription in latently VZV-infected HSN,
which is potentially mediated by the pVLT-ORF63 fusion protein.
Differential TSS usage of VLT between latently VZV-infected
TGs and lytically VZV-infected epithelial cells7 raises the question
as to whether transcription of distinct VLT isoforms depends on
infection phase or cell type. Here, we demonstrated that tran-
scription of specific VLT and VLT-ORF63 isoforms is determined
by the infection phase rather than the cell type. While both lytic and
latent transcript isoforms are predicted to encode the same protein
(s), the extended 5′-UTR in the lytic VLT and VLT-ORF63 tran-
scripts may confer new properties to the RNA. Alternative pro-
moter usage of viral genes between distinct but continuous infection
phases has been implicated as a switching mechanism of latency
and lytic infection among herpesviruses23–25, and may impact on
the localization and/or function of both type of VZV transcripts at
different infection phases.
Transcriptional profiling of reactivating neurons in our in vitro
HSN latency model revealed the presence of multiple viral tran-
scripts of all kinetic classes, including the VLT-ORF63 RNAs. By
contrast, when attempting to induce reactivation through
anisomycin-mediated activation of JNK signaling, previously
shown to be required for VZV reactivation and replication21, only
VLT-ORF63 transcription was consistently induced along with
higher expression levels of VLT. This provides a favorable
explanation as to how VZV initially reactivates from latency. As a
counterpoint, we do note the limitations imposed by using ani-
somycin to show a direct link between JNK signaling and com-






















































































































































































































































































































































Fig. 4 Effect of anisomycin treatment on VZV transcription in latently VZV-infected sensory neurons in vitro. a RT-qPCR analysis for transcription
across VLT and ORF63 loci in latently VZV-infected human iPSC-derived sensory neurons (HSN) cultures (n= 3). Data on individual HSN culture
experiments are shown as unique symbols. b, c Latently VZV-infected HSN cultures were depleted of neurotrophic factors (NGF [nerve growth factor],
GDNF [glial-derived neurotrophic factor], BDNF [brain derived neurotrophic factor] and NT-3 [neurotrophin-3]) and treated with anti-NGF antibody (Ab)
for 14 days. In total, n= 40 independent cultures were subjected to reactivation stimuli. b Representative examples of a HSN cultures showing complete
reactivation (2/40) and early/abortive reactivation (38/40) by infectious focus forming assay after transferring HSN onto ARPE-19 cells. c Representative
examples of viral gene expression in cultures showing complete reactivation (n= 1 shown; white circle) and early/abortive reactivation (n= 5 shown;
colored triangles). d, e HSN cultures were treated with d anisomycin (n= 6), or e DMSO as solvent control (n= 3) at both the somal and axonal
compartment for 1 h, washed twice and cultured for 7 days before RT-qPCR analysis. Data on individual HSN culture experiments are shown as unique
symbols and/or colors. Only VLT exon 1–2 is shown as representative of VLT. Source data are provided as a Source Data file (a–e).
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synthesis and just 1 h exposure to anisomycin induces a terminal
decline of neuronal cultures with death occurring within 14 days
of treatment, regardless of whether cells were latently VZV-
infected or not. Hence, further studies are needed to delineate the
mechanisms by which JNK signaling regulates VZV gene
expression and reactivation in latently VZV-infected HSN.
The VLT63-1, but not VLT63-2 isoform induced broad lytic
viral gene transcription in latently VZV-infected HSN cultures.
While these two isoforms differ only by the partial presence/
absence of VLT core exon 5, only VLT63-1 encodes for the
pVLT-ORF63, suggesting that the encoded protein and not the
transcript itself regulates transcription of VZV genes. Canonical
pORF63 has been reported to both positively and negatively affect
VZV gene transcription during lytic infection26,27, depending on
its phosphorylation status and cell type analyzed28. Here, we
showed that pORF63 induces expression of IE transcript RNA 61-
1 encoding the promiscuous transactivator pORF6129 and the E
transcript RNA 16-1, but not any of the other analyzed VZV IE,
E, or L genes in our in vitro HSN latency model. By contrast,
pVLT-ORF63 induced expression of multiple VZV transcripts of
all kinetic classes. Notably, in addition to its transcriptional reg-
ulatory activities, VZV pORF63 was reported to protect neurons
from apoptotic cell death and to antagonize innate antiviral
immune responses30–32. Further studies are required to
determine whether pVLT-ORF63 similarly modifies apoptosis
and immune pathways. Overall, the data suggest a key role for
pVLT-ORF63 in the initiation of VZV reactivation and empha-
size the importance of uncharacterized cellular factors and/or
other viral factors that are required for complete VZV reactiva-
tion for future studies.
Endogenous pVLT-ORF63 protein expression in human TG
and in vitro HSN latency model was analyzed, however, IHC
staining using the polyclonal chicken anti-pVLT-ORF63 antibody
as well as the polyclonal rabbit anti-pVLT antibody was unfor-
tunately found to result in high levels of non-specific background
staining in neuronal tissue (staining with the polyclonal rabbit
anti-pVLT antibody in HSN is shown in Supplementary Fig. 6).
Notably, in the past we have stained substantial numbers of
human TG using a highly potent pORF63-specific mAb (which
will recognize both cognate pORF63 and pVLT-ORF63) and
never observed any specific pORF63/pVLT-ORF63 staining33,
while others reported that detection of pORF63/pVLT-ORF63 is
extremely rare and possibly associated with reactivation34.
Combined, the data indicate that either pVLT-ORF63 is not
expressed or expressed at very low quantities, below the sensi-
tivity of IHC, in latently VZV-infected human TG and HSN.
HSV reactivation has been proposed to consist of two distinct
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c
RNA 16 RNA 29 RNA 31 RNA 66 RNA 68
d
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Fig. 5 Effect of ectopic VLT-ORF63 expression on VZV gene expression in latently VZV-infected sensory neurons in vitro. At 14 days after
establishment of VZV latency in human iPSC-derived sensory neurons (HSN), following VZV genes were transduced by replication incompetent lentivirus
vectors: empty vector (white), ORF63 (grey), VLT63-1 (purple) and VLT63-2 (cyan). Transduced HSN were cultured for 14 days (n= 4 replicates/vector)
and subjected to RT-qPCR analysis. Technical duplicates were utilized per sample and all the biologically independent data is shown as unique symbols for
a endogenous or transduced VZV genes, b IE genes, c E genes, and d L genes. Source data are provided as a Source Data file.
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designated as animation35 or Phase I36,37 is characterized by
generalized viral gene derepression36,38, in contrast the second
wave (Phase II) is identical to the cascade observed during acute
infection. Transition from latency to Phase I and Phase I to Phase
II might work as checkpoints, determining whether the virus
should complete reactivation or halt reactivation and re-enter
latency36. While we do not know whether animation/Phase I
occurs during VZV reactivation, broad transcription of viral
genes of all kinetic classes was induced by reactivation stimuli,
occasionally leading to complete reactivation in our in vitro HSN
latency model. Notably, our data demonstrates that broad VZV
transcription is initiated by VLT-ORF63 transcription/pVLT-
ORF63 translation, unlike Phase I of HSV reactivation for which
no viral initiator has been proposed to drive HSV gene expres-
sion. Thus, there might be critical differences between the
mechanism(s) governing HSV and VZV latency and reactivation.
Taken together, our discovery of the VLT-ORF63 fusion
transcripts in VZV-infected human TG and the ability of the
encoded pVLT-ORF63 fusion protein to act as an initiator of viral
gene expression during reactivation in our in vitro HSN latency
model provides critical new insights into how VZV latency and
reactivation are governed. Further studies using the HSN VZV
latency model, combined with careful analyses of human ganglia,
provides a new platform to dissect the cellular and viral molecular
mechanisms controlling VZV latency and reactivation. VZV is
the only human herpesvirus for which vaccines are licensed.
However, the live-attenuated varicella vaccine establishes latency
and may reactivate to cause disease, while adjuvanted recombi-
nant zoster vaccine is highly effective against HZ prevention but
not suited for childhood varicella vaccination. The discovery of
VLT-ORF63 and its role in reactivation provides new insight that
will inform efforts to improve varicella vaccines.
Methods
Human clinical specimens. Human TG specimens were obtained (Supplementary
Tables 1 and 2) from the Netherlands Brain Bank (Netherlands Institute for
Neuroscience; Amsterdam, the Netherlands). All donors had provided written
informed consent for brain autopsy and the use of material and clinical infor-
mation for research purposes. All study procedures were performed in compliance
with relevant laws in The Netherlands and Japan, institutional guidelines approved
by the local ethical committee (VU University Medical Center, Amsterdam, project
number 2009/148, and Kobe University, Kobe, project number 170107) and in
accordance with the ethical standards of the Declaration of Helsinki. TG biopsies
were either formalin-fixed and paraffin-embedded (FFPE) for in situ analysis or
snap-frozen in liquid nitrogen and stored at −80 °C for nucleic acid extraction.
FFPE skin punch biopsies of one healthy control subject and two herpes zoster skin
lesions were obtained for diagnostic purposes. According to the institutional “Opt-
Out” system (Erasmus MC, Rotterdam, the Netherlands), which is defined by the
National “Code of Good Conduct” [Dutch: Code Goed Gebruik, May 2011], the
surplus human herpes zoster FFPE tissues were available for the current study.
Cells. Human iPSC-derived sensory neuron (HSN) progenitors (Axol Bioscience)
were plated on a 24-well plate (1 × 105 cells/well), CELLview Slide (Greiner Bio-
One) (1 × 104 cells/well) or a microfluidic platform (7.5 × 104 cells/sector) in
Neuronal Plating-XF Medium (Axol Bioscience). Fabrication of a microfluidic
platform was previously described39. Prior to plating the HSN progenitors, a plate,
slide or microfluidic platform was coated with poly-L-ornithine (Sigma-Aldrich)
(20 µg/mL) or poly-D-lysin (Sigma-Aldrich) (200 µg/mL) in molecular grade water
at room temperature overnight, washed with distilled water twice and coated with
Matrigel (Corning) (1 µg/mL) in Knockout DMEM/F-12 medium (Thermo Fisher
Scientific) for 2 h at room temperature following overnight incubation at 37 °C in a
humified 5% CO2 incubator. At 1 day after plating, the medium was replaced to the
complete maintenance medium consisted with Neurobasal Plus Medium, B-27 Plus
Supplement (2% [vol/vol]), N2 Supplement (1% [vol/vol]), GlutaMAX-I (2 mM)
(Thermo Fisher Scientific), ascorbic acid (200 µM; Sigma-Aldrich), GDNF (glial-
derived neurotrophic factor) (25 ng/mL), NGF (nerve growth factor) (25 ng/mL),
BDNF (brain derived neurotrophic factor) (10 ng/mL) and NT-3 (neurotrophin-3)
(10 ng/mL) (Peprotech) for sensory neuronal maturation. Two days after the
plating the HSN progenitors, cells were treated with the complete maintenance
medium with mitomycin C (2.5 µg/mL; Nacalai Tesque, Inc.) for 2 h to eliminate
proliferating cells, washed with the complete medium twice and culture in the
complete maintenance medium at least 7 weeks with replacing half the volume of
culture with the fresh medium every 4 days. During maturation in the microfluidic
platform, culture medium level in the axonal compartment was kept higher than
that in the somal compartment to prevent cell migration to the axonal compart-
ment. The maturation of sensory neurons was characterized previously12. Human
retinal pigmented epithelium ARPE-19 cells (American Type Culture Collection
[ATCC] CRL-2302) were maintained in DMEM/F-12+GlutaMAX-I (Thermo
Fisher Scientific) supplemented with heat-inactivated 8% FBS (foetal bovine serum;
Sigma-Aldrich). Human embryonic kidney (HEK) 293T cells (ATCC CRL-3216)
were cultured in DMEM+GlutaMAX-I (Thermo Fisher Scientific) supplemented
with heat-inactivated 8% FBS.
VZV infections. VZV strain pOka (parental Oka) was maintained in and the cell-
free virus was prepared from ARPE-19 cells as described previously for human
embryonic lung fibroblast MRC-5 cells40. For lytic infection in ARPE-19 cells, cells
were plated on 12-well plate at a density of 1 × 105 cells/well 2 days before infec-
tion, infected with the cell-free virus (3 × 103 pfu [plaque-forming unit] to 1 well)
for 1 h in 500 µL medium, washed with the medium twice and cultured for 4 days.
For lytic infection for HSN, cells were maturated as described above, infected with
the cell-free virus (4 × 103 pfu to 1 well) at 52 days after maturation for 2 h in 400
µL medium, washed with the medium twice, treated with low pH buffer (40 mM
sodium citrate, 10 mM potassium chloride, 135 mM sodium chloride [pH 3.2]) for
30 seconds (sec), washed with the medium once and cultured for 2 weeks to obtain
efficient lytic infection as described12.
For in vitro VZV latency, the method was established previously for human
embryonic stem cell-derived neurons19 and applied for HSN12. Briefly, HSN were
maturated on a microfluidic platform for 54 days and infected via axonal chamber
with 10 µL of the cell-free virus (4 × 104 pfu/mL titrated on ARPE-19 cells) in 20 µL
total volume. After 2 h infection, inoculum was removed, and axons were treated
with the low pH buffer for 30 sec, washed with the medium and cultured for
2 weeks. To reactivate VZV from sensory neuronal latency, GDNF, NGF, BDNF,
and NT-3 were depleted from and anti-NGF polyclonal antibody (50 µg/mL) was
added to the complete maintenance medium, and cultures were maintained for
2 weeks. For chemical induced reactivation, latently VZV-infected HSN was treated
with JNK activator, anisomycin (20 µg/mL) or solvent control (DMSO [dimethyl
sulfoxide]) for 1 h from both axonal and somal compartment, washed with the
medium twice and cultured in the complete maintenance medium without GDNF,
NGF, BDNF and NT-3 for 1 week. For VZV gene transduction, latently VZV-
infected HSN was transduced by lentivirus vector for 2 h from somal compartment
with mixing by pipetting at 30 minutes (min) and 1.5 h after transduction, cultured
overnight and replaced the medium in both somal and axonal compartments with
the fresh complete maintenance medium without GDNF, NGF, BDNF and NT-3
for 2 weeks. The complete reactivation was confirmed by the formation of
infectious foci after transferring the HSN onto and co-culturing with ARPE-19 cells
for 7 days as described below.
DNA, RNA, and cDNA. DNA and RNA were isolated from human TGs (n= 4)
(Supplementary Table 2) as described previously7. DNA and RNA from VZV-
infected ARPE-19 cells or HSN were isolated as described previously7 with slight
modifications using the FavorPrep Blood/Cultured Cell Total RNA Mini Kit
(FAVORGEN BIOTECH) in combination with the NucleoSpin RNA/DNA buffer
set (Macherey-Nagel). DNA was first eluted from the column in 80 µL DNA elu-
tion buffer, the column was treated with recombinant DNase I (20 units/100 µL;
Roche Diagnostics) for 30 min at 37 °C and RNA was eluted in 50 µL nuclease free
water. RNA was directly treated with Baseline-ZERO DNase (2.5 units/50 µL;
Epicentre) for 30 min at 37 °C (all the RNA), and further purified by Dynabeads
mRNA purification kit (Thermo Fisher Scientific) (TG RNA) or enriched by
Agencourt RNAClean XP (Beckman Coulter) (in vitro latency RNA). cDNA was
synthesized with 12 µL of RNA and anchored oligo(dT)18 primer in a 20 µL
reaction using the Transcriptor First Strand cDNA synthesis kit at 55 °C for 30 min
for reverse transcriptase reaction (Roche Diagnostics).
Quantitative PCR and 5′-RACE analysis. DNA or cDNAs were subjected to
quantitative PCR (qPCR) using KOD SYBR qPCR Mix (TOYOBO) in the StepO-
nePlus Real-time PCR system (Thermo Fisher Scientific) (1 µL of DNA or cDNA per
10 µL reaction in duplicate). All the primer sets used for qPCR (Supplementary
Table 1) were first confirmed for the amplification rate (98-100%) and their own
melting temperatures using 10–106 copies (tenfold dilution) of pOka-BAC genome,
VLT-ORF63 plasmids or purified PCR product spanning from VLT exon A to exon 1
of cDNA and the lack of non-specific amplification using water (except a primer pair
for RNA 31 which signal was detected with Ct value of 36.25 cycles with distinct
melting temperature [69.79 °C] from authentic ORF31 amplicon [80.97 °C]). Due to
the partially antisense nature of VLT via exon 3 and exon 4 against RNA 61, a primer
pair of exons 3 and 4 detected both VLT and RNA 61, thus a primer pair of exons 2
and 4 was used for lytic infection instead a primer pair of exons 3 and 4 used for
in vivo and in vitro latency in which RNA 61 is absent. The qPCR program is as
follows; 95 °C for 2 min (1 cycle), 95 °C for 10 sec and 60 °C 15 sec (40 cycles), and 60
to 95 °C for a dissociation curve analysis to discriminate non-specific signal if any.
Data are presented as relative transcription level of VZV gene to cellular beta-actin
defined as 2-(Ct-value VZV gene – Ct-value beta-actin).
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5′-RACE analysis was performed using SMARTer RACE 5′/3′ kit and In-Fusion
HD Cloning kit according to the manufacturer’s instructions with slight
modifications (Clontech). 5′-RACE ready cDNA was synthesized from purified
mRNA (TG) or total RNA (HSN) with SMARTerIIA Oligonucleotide and 5′-
RACE CDS Primer A. KOD FX Neo PCR system (TOYOBO) was used for 5′-
RACE PCR and the program was 1 cycle of 94 °C for 2 min and 30 cycles of 95 °C
for 10 sec and 68 °C for 1 min. Initial PCR was performed by Universal Primer Mix
(a mixture of Universal Primer Long and Universal Primer Short) and
InFusionVLTexon5R104799 for VLT or InFusionORF63R805 for VLT-ORF63
fusions. Nested PCR, if necessary, was carried out using Universal Primer Long and
InFusionVLTexon4R10361 for VLT or InFusionORF63R622 for VLT-ORF63
fusions. The 5′-RACE PCR products were cloned into linearized pRACE cloning
vector and sequenced by M13forward or M13reverse on the ABI Prism 3130 XL
Genetic Analyzer using the BigDye v3.1 Cycle Sequencing Kit (Thermo Fisher
Scientific). All the primers used for 5′-RACE analysis are listed in Supplementary
Table 4.
Direct RNA sequencing and cDNA sequencing on nanopore array. Direct RNA
sequencing libraries were generated from 117 to 153 ng of poly(A) RNA, isolated
using Dynabeads mRNA purification kit. Isolated poly(A) RNA was subsequently
spiked with 0.5 µl of a synthetic Enolase 2 (ENO2) calibration RNA (Oxford
Nanopore Technologies Ltd.) and sequenced on a MinION MkIb with R9 flow cells
(Oxford Nanopore Technologies Ltd.) for 40 h, as previously described14. cDNA
sequencing libraries were generated from 1 ng of poly(A) RNA, isolated using
Dynabeads mRNA purification kit using cDNA-PCR Sequencing kit (SQK-
PCS109) (Oxford Nanopore Technologies Ltd.) and sequenced on a MinION MkIb
with R9 flow cells for 40 h using the command software MinKNOW v3.1.9 (Oxford
Nanopore Technologies). Following basecalling with Guppy v3.2.2, only the reads
passing filter were used. Error-correction was performed using proovread as
described previously14. Nanopore read data were aligned to the VZV strain dumas
genome (X04370.1) using MiniMap2 v2.1541 and parsed using SAMtools v1.942
and BEDTools v2.27.143 before visualizing using the Bioconductor v3.11 and
Gviz v1.32.
Multiplex fluorescent RNA in situ hybridization in human cadaveric TG. FFPE
latently VZV-infected human TG (n= 7) (Supplementary Table 3), human zoster
skin biopsies, and lytically VZV-infected ARPE-19 cells were analyzed by multiplex
fluorescent in situ hybridization (mFISH) using the RNAScope Multiplex Fluor-
escent Reagent Kit v2 (Advanced Cell Diagnostics) according to the manufacturer’s
instructions. Briefly, deparaffinized 5 µm-thick tissue sections were incubated with
probes directed to VZV RNA 9, RNA 63 and VLT exons 2–5. RNA integrity and
mFISH specificity were demonstrated by staining TGs for ubiquitously expressed
cytoplasmic transcript UBC (human ubiquitin C), nuclear transcript MALAT1
(human metastasis-associated lung adenocarcinoma transcript 1) (positive con-
trols) and bacterial dihydrodipicolinate reductase (DAPB) (negative control probe)
(Supplementary Fig. 2C). Probes were designed by Advanced Cell Diagnostics.
Sections were mounted with Prolong Diamond antifade mounting medium and
confocal microscopic analysis was performed on a Zeiss LSM 710 confocal
microscope, as described44.
Replication incompetent lentivirus vectors. VZV genes, ORF63, VLT63-1, or
VLT63-2 were amplified by PCR of cDNA from VZV pOka-infected ARPE-19
cells. The PCR product was digested with SalI restriction enzyme and cloned into
CS-CA-MCS plasmid (Riken BioResource Research Center) via SalI site (ORF63)
or directly cloned into linearized CS-CA-MCS (VLT63-1 and VLT63-2) using In-
Fusion HD Cloning kit according to the manufacturer’s instruction (Clontech).
The primer sets used for cDNA cloning into the CS-CA-MCS plasmid are listed in
Supplementary Table 4. HEK293T cells (4 × 106 cells) were plated onto a 10 cm
dish, transfected with CS-CA-MCS or CS-CA-VZV (20 µg) and packaging plas-
mids, pCAG-HIVgp (5 µg) and pCMV-VSV-G-RSV-Rev (5 µg) (Riken BioR-
esource Research Center) using PEImax solution (60 µL) (Polysciences) prepared
in KnockoutDMEM/F-12 (500 µL) at 6 h post plating and cultured overnight in 8%
CO2 incubator in 10 mL DMEM+GlutaMAX-I with heat-inactivated 8% FBS.
Whole culture medium was changed with the fresh medium at 16 h after trans-
fection and cells were cultured for another 48 h. Supernatant (20 mL) were filtrated
through 0.45 µm syringe filter (Pall), mixed with 5 mL of PEG6000 (50% [wt/vol]
in PBS), 1.7 mL of 5M NaCl and 2.6 mL of PBS, and rotated in a 50 mL conical
tube at 4 °C at least 8 h. After centrifugation at 7000 × g for 10 min, supernatant
was removed, pellet was resuspended in 300 µL of KnockoutDMEM/F-12, ali-
quoted out in four tubes and stored at −80 °C until use. Quantity of each repli-
cation incompetent lentivirus vector was measured by qPCR of cDNA synthesized
with random hexamer from genomic RNA packaged in enriched pseudo virion
using the primer set, CSCA1831F and CSCA1969R (Supplementary Table 1)
detecting upstream promoter region in CS-CA-MCS plasmid and equal amount of
virus were used for transductions.
Antibodies. Chicken polyclonal antibody (pAb) against 24 aa linker peptide
(GFVRFITRQRRVGFKGKGYYGPKD) of pVLT-ORF63 fusion protein, anti-
pVLT-ORF63 pAb was generated and purified through an immunogen conjugated
peptide column (Cosmo Bio). Rabbit anti-pVLT pAb, rabbit anti-pORF63 pAb7,
mouse anti-pORF63 monoclonal antibody (mAb)(clone VZ63.08)45, and mouse
anti-glycoprotein E (gE) mAb46 were described previously. Anti-alpha tubulin
mAb (clone B-5-1–2; Sigma-Aldrich) and sheep anti-NGF pAb (EMD Millipore)
are commercially available. Alexa Fluor 488- or Alexa Fluor 647-conjugated
donkey anti-mouse IgG, Alexa Fluor 594-conjugated donkey anti-rabbit IgG
(Thermo Fisher Scientific) and Alexa Fluor 488-conjugated donkey anti-chicken
IgY (Jackson ImmunoResearch Laboratories) were used for secondary Abs for
indirect immunofluorescent assay. Anti-mouse IgG HRP-linked Whole Ab Sheep
or anti-rabbit IgG HRP-linked Whole Ab Donkey (GE Healthcare Bio-Sciences)
were used as secondary Abs for immunoblotting.
Immunofluorescent staining, confocal microscopy, infectious foci staining,
and immunoblotting. Cells on CELLview slide were fixed with 4% (vol/vol) par-
aformaldehyde (PFA)/PBS (Nacalai Tesque, Inc.) at room temperature for 20 min,
permeabilized with 0.1% Triton X-100/4% PFA/PBS at room temperature for 20
min, and incubated with human Fc receptor blocking solution (5% FBS/PBS
containing 10% of Clear Back [MBL]) at room temperature for 1 h. Cells were
stained with the primary Abs diluted in a solution (5% FBS/PBS) overnight at 4 °C
(1:100 for anti-pVLT pAb, anti-pVLT-ORF63 pAb and anti-pORF63 mAb, 1:300
for all Abs against neuronal markers, 1:500 for anti-pORF63 pAb), washed with
0.1% Tween 20/PBS (PBS-T) for 5 min 3 times, stained with the secondary Abs
(1:300) diluted in 5% FBS/PBS at room temperature for 1 h, washed with PBS-T for
5 min 3 times, covered with VECTASHIELD Vibrance Antifade Mounting Med-
ium with DAPI (Vector Laboratories) and imaged by an FV1000D confocal
microscopy (Olympus).
Deparaffinized and rehydrated 5 µm FFPE sections of human herpes zoster skin
lesions and healthy control skin were subjected to heat-induced antigen retrieval
with citrate buffer (pH= 6.0), blocked and incubated with mouse anti-VZV
pORF63 Ab (1:1,500 dilution; kindly provided by Dr. Sadzot-Delvaux; Liege,
Belgium47), chicken anti-pVLT-ORF63 pAb (1:100 dilution) overnight at 4 °C.
Sections were subsequently incubated with Alexa Fluor 488- and Alexa Fluor 594-
conjugated goat-anti-mouse and goat-anti-chicken secondary antibodies (all
1:250 dilution) and sections were mounted with Prolong Diamond antifade
mounting medium with DAPI. Confocal microscopic analysis was performed as
described44.
To visualize infectious foci on ARPE-19 cells, cells were fixed with 4% PFA/PBS,
stained with anti-gE mAb (1:10 dilution in PBS), followed by anti-mouse IgG HRP-
linked whole Ab sheep (1:5,000 dilution in PBS), and reacted with 3, 3′, 5, 5′-
tetramethylbenzidine-H peroxidase substrate (Moss, Inc.).
Cells were incubated in RIPA lysis buffer (0.01 M Tris-HCl [pH 7.4], 0.15 M
NaCl, 1% sodium deoxycholate, 1% Nonidet P-40 and 0.1% SDS) on ice for 15 min,
sonicated in a water bath for 10 min, centrifuged at 20,000 × g for 15 min.
Supernatant was boiled with LDS Sample Buffer (4X) and Sample Reducing Agent
(10X) at 100 °C for 5 min (Thermo Fisher Scientific). Proteins were separated on 4-
12% Bis-Tris Plus Gel in MES SDS Running Buffer (200 V, 25 min), transferred
onto PVDF membrane (0.2 µm) using Mini Blot Module (20 V, 1 h) in Bolt
Transfer Buffer containing 10% methanol and 0.1% Bolt Antioxidant (Thermo
Fisher Scientific). The membrane was blocked in a blocking buffer (5% [wt/vol]
skimmed milk/0.1% Tween 20/PBS) at room temperature for 1 h, stained with
primary Abs diluted in the blocking buffer (1:1,000 for anti-pVLT pAb, 1:6,000 for
anti-pORF63 pAb and 1:10,000 for anti-alpha tubulin mAb) overnight at 4 °C,
washed with PBS-T for 5 min 3 times, stained with the secondary Abs diluted in the
blocking buffer (1:3,000) at room temperature for 30 min, and washed with PBS-T
for 5 min 3 times and PBS briefly once. Signals were visualized by Chemi-Lumi
One Super (Nacalai Tesque, Inc.) and captured using LAS4000mini (GE Healthcare
Bio-Sciences). A membrane stained with anti-pVLT pAb was stripped by WB
Stripping Solution Strong in accordance with the manufacturer’s manual (Nacalai
Tesque, Inc.) and reprobed with anti-alpha-tubulin mAb.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Basecalled fast5 nanopore dRNA- and cDNA-Seq datasets generated as part of this study
can be downloaded from the European Nucleotide Archive (ENA) under the following
study accession: PRJEB36978. Source data are provided with this paper.
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